keyword
MENU ▼
Read by QxMD icon Read
search

Veno-occlusive disease

keyword
https://www.readbyqxmd.com/read/29680515/safety-and-efficacy-of-once-daily-intravenous-busulfan-in-allogeneic-transplantation-a-matched-pair-analysis
#1
Shinichi Kako, Shinichiro Fujiwara, Miki Sato, Shun-Ichi Kimura, Hideki Nakasone, Kazuteru Ohashi, Toshiro Kawakita, Tetsuo Maeda, Takanobu Morishita, Ritsuro Suzuki, Takahiro Fukuda, Tatsuo Ichinohe, Mio Kurata, Yoshiko Atsuta, Yoshinobu Kanda
Compared with 4-times-daily infusion of intravenous busulfan (ivBU4), the safety and efficacy of once-daily infusion of ivBU (ivBU1) has not been fully clarified. We have been routinely using ivBU1 in a conditioning regimen in adult patients with myeloid malignancy who undergo allogeneic hematopoietic stem cell transplantation. In this study, a total of 91 patients who received ivBU1 for 2 days (n = 18) or 4 days (n = 73) in our institutions were compared with 273 control patients who received ivBU4, who were matched for age, sex, performance status, disease risk, conditioning regimen, and donor type, selected from the database of the Japanese Society for Hematopoietic Cell Transplantation using optimal matching algorithms...
April 19, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29650683/fda-approval-summary-mylotarg-for-treatment-of-patients-with-relapsed-or-refractory-cd33-positive-acute-myeloid-leukemia
#2
Kelly J Norsworthy, Chia-Wen Ko, Jee Eun Lee, Jiang Liu, Christy S John, Donna Przepiorka, Ann T Farrell, Richard Pazdur
On September 2, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin (GO; Mylotarg; Pfizer, New York City, NY) for treatment of relapsed or refractory (R/R) CD33-positive acute myeloid leukemia (AML) in patients 2 years of age and older. GO is a CD33-directed antibody drug conjugate linked to the cytotoxic antibiotic calicheamicin. It originally received accelerated approval for treatment of older patients with relapsed CD33-positive AML in 2000, but it was withdrawn from the market in 2010 when the confirmatory trial failed to demonstrate clinical benefit among safety concerns, such as a higher rate of induction fatalities on the GO combination arm compared with chemotherapy alone...
April 12, 2018: Oncologist
https://www.readbyqxmd.com/read/29628135/lung-transplantation-for-scleroderma-lung-disease-an-international-multicenter-observational-cohort-study
#3
Pauline Pradère, Igor Tudorache, Jesper Magnusson, Laurent Savale, Olivier Brugiere, Benoît Douvry, Martine Reynaud-Gaubert, Johanna Claustre, Aurélie Le Borgne, Are M Holm, Hans Henrik Schultz, Christiane Knoop, Laurent Godinas, Andrew J Fisher, Sandrine Hirschi, Jens Gottlieb, Jérôme Le Pavec
BACKGROUND: Due to its multisystemic nature, scleroderma is considered a relative contraindication to lung transplantation at many centers. However, recent studies suggest similar post-transplant outcomes in patients with scleroderma compared to those with other causes of interstitial lung disease (ILD). Furthermore, it remains unknown whether scleroderma-associated pulmonary arterial hypertension (PAH) influences post-transplant outcomes. Our objective in this study was to assess the indications, survival, and prognostic factors of lung or heart-lung transplantation for scleroderma lung disease...
March 15, 2018: Journal of Heart and Lung Transplantation
https://www.readbyqxmd.com/read/29562469/-treatment-of-four-cases-of-fanconi-anemia-by-allogeneic-hematopoietic-stem-cell-transplantation-with-low-intensity-conditional-regimen
#4
H Hou, Y H Yao, J Lu, P F Xiao, X N Bian, H Liu, D X Hu, J Ling, J Li, Z Zhai, L J Kong, S Y Hu
Objective: To evaluate the efficiency and safety of low intensity conditional regimen for children with Fanconi anemia (FA) receiving allogenic hematopoietic stem cells transplantation (allo-HSCT). Methods: Four patients diagnosed as Fanconi anemia were enrolled in this study. One patient received HLA-identical sibling donor hematopoietic stem cell transplantation, two patients underwent unrelated donor matched (UD) HSCT, and one patient received unrelated cord blood transplantation. The conditional regimen consisted of Busulfan with low dose of cyclophosphamide...
March 14, 2018: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/29548663/clinical-prediction-score-for-identifying-patients-with-pulmonary-veno-occlusive-disease-pulmonary-capillary-hemangiomatosis
#5
Aiko Ogawa, Yukari Takahashi, Hiromi Matsubara
BACKGROUND: Pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH) are rare causes of pulmonary hypertension. Although diagnosis is based on pathological findings, an early diagnosis is crucial because of poor prognosis compared to other types of pulmonary hypertension. Furthermore, vasodilators may cause fatal pulmonary edema in patients with PVOD/PCH. This study aimed to identify specific characteristics for patients with PVOD/PCH to clinically diagnose PVOD/PCH...
March 13, 2018: Journal of Cardiology
https://www.readbyqxmd.com/read/29524571/risk-assessment-of-pyrrolizidine-alkaloids-in-food-of-plant-and-animal-origin
#6
Birgit Dusemund, Nicole Nowak, Christine Sommerfeld, Oliver Lindtner, Bernd Schäfer, Alfonso Lampen
Acute liver toxicity, specifically in the form of hepatic veno-occlusive disease (HVOD), is known from reports on human poisonings following ingestions of 1,2-unsaturated pyrrolizidine alkaloids (PAs) containing herbs. Recently PA exposure via common foods contaminated via PA-producing plants raised concern, especially regarding the potential of genotoxicity and carcinogenicity. The health risks related to the estimated exposures to PAs from food were assessed. With respect to common foods, herbal teas and teas are the main sources through which consumers can be exposed to PAs...
March 7, 2018: Food and Chemical Toxicology
https://www.readbyqxmd.com/read/29524230/transfusion-transmitted-malaria-masquerading-as-sickle-cell-crisis-with-multisystem-organ-failure
#7
Cheryl L Maier, Phillip J Gross, Christina L Dean, Satheesh Chonat, Andrew Ip, Morgan McLemore, Fuad El Rassi, Sean R Stowell, Cassandra D Josephson, Ross M Fasano
BACKGROUND: Fever accompanying vaso-occlusive crisis is a common presentation in patients with sickle cell disease (SCD) and carries a broad differential diagnosis. Here, we report a case of transfusion-transmitted malaria in a patient with SCD presenting with acute vaso-occlusive crisis and rapidly decompensating to multisystem organ failure (MSOF). CASE REPORT: An 18-year-old African American male with SCD was admitted after multiple days of fever and severe generalized body pain...
March 9, 2018: Transfusion
https://www.readbyqxmd.com/read/29519713/sinusoidal-obstruction-syndrome-veno-occlusive-disease-complication-in-lymphoma-patients-treated-with-oxaliplatin-based-regimen-a-case-series-report
#8
E Bernichon, E Daguenet, C Molla, J Cornillon, C Lejeune, F Casteillo, D Guyotat, E Tavernier
AIM: SOS/VOD is a relevant clinical syndrome that usually appears early after hematopoietic stem cell transplantation. The purpose of this article was to report a case series of SOS/VOD in non-susceptible patients and draw physicians' attention to the plausible relationship between liver injury and oxaliplatin-based chemotherapy, preceding autologous transplantation. METHODS: In this study, we report a case series of SOS/VOD in 4 lymphoma patients following autologous transplantation...
March 5, 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29508628/drug-associated-pulmonary-arterial-hypertension
#9
Michael McGee, Nicholas Whitehead, Jennifer Martin, Nicholas Collins
INTRODUCTION: While pulmonary arterial hypertension remains an uncommon diagnosis, various therapeutic agents are recognized as important associations. These agents are typically categorized into "definite", "likely", "possible", or "unlikely" to cause pulmonary arterial hypertension, based on the strength of evidence. OBJECTIVE: This review will focus on those therapeutic agents where there is sufficient literature to adequately comment on the role of the agent in the pathogenesis of pulmonary arterial hypertension...
March 6, 2018: Clinical Toxicology
https://www.readbyqxmd.com/read/29501213/-pulmonary-veno-occlusive-disease
#10
REVIEW
A Boucly, B Girerd, D Bourlier, S Nemlaghi, J Caliez, L Savale, X Jaïs, P Dorfmüller, G Simonneau, O Sitbon, M Humbert, D Montani
Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hypertension (PH) characterized by preferential remodelling of pulmonary venules and angioproliferation. PVOD term includes idiopathic, heritable (biallelic mutations of EIF2AK4 gene), drugs and toxins induced (alkylating agents, organic solvents) and connectivite-associated forms (especially systemic-sclerosis associated form). PVOD and pulmonary arterial hypertension (PAH) share a similar clinical presentation. Lung biopsy is contraindicated in PVOD due to high risk of life-threatening bleeding...
February 28, 2018: Revue des Maladies Respiratoires
https://www.readbyqxmd.com/read/29477779/defibrotide-for-sinusoidal-obstruction-syndrome-veno-occlusive-disease-prophylaxis-in-high-risk-adult-patients-a-single-center-experience-study
#11
Adrien Picod, Agnès Bonnin, Giorgia Battipaglia, Federica Giannotti, Annalisa Ruggeri, Eolia Brissot, Florent Malard, Clémence Médiavilla, Ramdane Belhocine, Anne Vekhoff, Mor Sény Gueye, Simona Lapusan, Rosa Adaeva, Françoise Isnard, Ollivier Legrand, Minh-Tam Baylatry, Anne-Christine Joly, Myriam Labopin, Rémy Duléry, Mohamad Mohty
Sinusoidal obstruction syndrome (SOS), also known as hepatic veno-occlusive disease (VOD) is a serious complication after hematopoietic stem cell transplantation (HSCT). SOS/VOD usually occurs within 3 weeks of HSCT but the 2016 EBMT diagnosis criteria have been revised to include late forms. Prophylactic use of defibrotide is recommended in the pediatric setting but its value remains uncertain in the adult population. We report here a single center series of 63 adult patients considered at high risk of SOS/VOD, receiving defibrotide prophylaxis in combination with ursodeoxycholic acid between May 2012 and August 2016...
February 22, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29476018/fda-approval-gemtuzumab-ozogamicin-for-the-treatment-of-adults-with-newly-diagnosed-cd33-positive-acute-myeloid-leukemia
#12
Emily Y Jen, Chia-Wen Ko, Jee Eun Lee, Pedro L Del Valle, Antonina Aydanian, Charles Jewell, Kelly J Norsworthy, Donna Przepiorka, Lei Nie, Jiang Liu, Christopher M Sheth, Marjorie Shapiro, Ann T Farrell, Richard Pazdur
On September 1, 2017, FDA granted approval for gemtuzumab ozogamicin (GO) (Mylotarg; Pfizer, Inc) in combination with daunorubicin and cytarabine (DA) and as a monotherapy for the treatment of adult patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML). GO is a CD33-targeted antibody-drug conjugate joined to calicheamicin. Approval of GO combination treatment was based on a randomized trial of 271 patients with newly-diagnosed AML treated with DA with or without 3 mg/m2 fractionated GO, which resulted in an event-free survival (EFS) of 13...
February 23, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29469225/successful-hematopoietic-stem-cell-transplantation-for-osteopetrosis-using-reduced-intensity-conditioning
#13
Bella Shadur, Irina Zaidman, Adeeb NaserEddin, Elana Lokshin, Fatma Hussein, Hodaya Cohen Oron, Batia Avni, Sigal Grisariu, Polina Stepensky
BACKGROUND: Infantile malignant osteopetrosis (IMO) is an autosomal recessive condition characterized by defective osteoclast activity, with hematopoietic bone marrow transplant being the only available cure. Over the past several years, new conditioning regimes and donor options have emerged, thus extending the possibility of cure to a greater number of patients and improving the outcomes of bone marrow transplant. Here we detail the outcomes of bone marrow transplant in a cohort of 31 patients treated with a combination of fludarabine, treosulphan, thiotepa, and antithymocyte globulin...
February 22, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29428338/extracorporeal-membrane-oxygenation-support-during-pregnancy-in-pulmonary-veno-occlusive-disease
#14
Carlos Ortiz-Bautista, María Jesús López-Gude, Jesús Grande García, José Luis Pérez-Vela, Virginia Pérez-González, Pilar Escribano-Subías
No abstract text is available yet for this article.
February 7, 2018: Revista Española de Cardiología
https://www.readbyqxmd.com/read/29425462/challenges-in-pulmonary-hypertension-controversies-in-treating-the-tip-of-the-iceberg
#15
Jason M Elinoff, Richa Agarwal, Christopher F Barnett, Raymond L Benza, Michael J Cuttica, Ahmed M Gharib, Michael P Gray, Paul M Hassoun, Anna R Hemnes, Marc Humbert, Todd M Kolb, Tim Lahm, Jane A Leopold, Stephen C Mathai, Vallerie V McLaughlin, Ioana R Preston, Erika B Rosenzweig, Oksana A Shlobin, Virginia D Steen, Roham T Zamanian, Michael A Solomon
The Critical Care Medicine Department of the National Institutes of Health Clinical Center and the Pulmonary Hypertension Association held a joint symposium to discuss "Challenges in Pulmonary Hypertension: Beating, Breathing, and Beyond." Communities of interest including patient advocates, clinicians, and academic investigators gathered together to raise awareness and highlight the challenges in diagnosing and treating pulmonary hypertension (PH). The current symposium focused on whether or not pulmonary arterial hypertension specific treatments are warranted as therapies for PH due to heart failure with preserved ejection fraction, interstitial lung disease, and pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis...
February 9, 2018: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/29413507/respiratory-effects-of-trichloroethylene
#16
REVIEW
Orianne Dumas, Thomas Despreaux, Frédéric Perros, Edmund Lau, Pascal Andujar, Marc Humbert, David Montani, Alexis Descatha
Trichloroethylene (TCE) is a chlorinated solvent that has been used widely around the world in the twentieth century for metal degreasing and dry cleaning. Although TCE displays general toxicity and is classified as a human carcinogen, the association between TCE exposure and respiratory disorders are conflicting. In this review we aimed to systematically evaluate the current evidence for the respiratory effects of TCE exposure and the implications for the practicing clinician. There is limited evidence of an increased risk of lung cancer associated with TCE exposure based on animal and human data...
January 2018: Respiratory Medicine
https://www.readbyqxmd.com/read/29396857/flai-fludarabine-cytarabine-idarubicin-plus-low-dose-gemtuzumab-ozogamicin-as-induction-therapy-in-cd33-positive-aml-final-results-and-long-term-outcome-of-a-phase-ii-multicenter-clinical-trial
#17
Anna Candoni, Cristina Papayannidis, Giovanni Martinelli, Erica Simeone, Michele Gottardi, Ilaria Iacobucci, Filippo Gherlinzoni, Giuseppe Visani, Michele Baccarani, Renato Fanin
The aim of this prospective clinical trial was to evaluate the efficacy and safety of a combination of Gemtuzumab-Ozogamicin (GO) and FLAI scheme (fludarabine, cytarabine, idarubicin) as a first-line therapy in CD33 positive acute myeloid leukemia (AML). We treated 130 consecutive patients, aged <65, with a median age of 52 years (range, 18-65). FLAI-GO induction regimen included fludarabine (30 mg/sqm) and cytarabine (2 g/sqm) on days 1-5; idarubicin (10 mg/sqm) on days 1, 3, and 5; and GO (3 mg/sqm) on day 6...
February 2, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29381191/efficacy-and-safety-analysis-by-age-cohort-of-inotuzumab-ozogamicin-in-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia-enrolled-in-ino-vate
#18
Elias J Jabbour, Daniel J DeAngelo, Matthias Stelljes, Wendy Stock, Michaela Liedtke, Nicola Gökbuget, Susan O'Brien, Tao Wang, M Luisa Paccagnella, Barbara Sleight, Erik Vandendries, Anjali S Advani, Hagop M Kantarjian
BACKGROUND: Inotuzumab ozogamicin (InO) has demonstrated efficacy and tolerability in patients aged 18 to 78 years with relapsed/refractory acute lymphoblastic leukemia (ALL) in the INO-VATE trial. This subset analysis compared the efficacy and safety of InO in younger and older patients. METHODS: Intent-to-treat analyses of morphologic responses and overall survival (OS) included 326 randomized patients, and safety assessments included 307 patients receiving 1 or more doses of the study treatment...
January 30, 2018: Cancer
https://www.readbyqxmd.com/read/29352703/inotuzumab-ozogamicin-in-combination-with-low-intensity-chemotherapy-for-older-patients-with-philadelphia-chromosome-negative-acute-lymphoblastic-leukaemia-a-single-arm-phase-2-study
#19
Hagop Kantarjian, Farhad Ravandi, Nicholas J Short, Xuelin Huang, Nitin Jain, Koji Sasaki, Naval Daver, Naveen Pemmaraju, Joseph D Khoury, Jeffrey Jorgensen, Yesid Alvarado, Marina Konopleva, Guillermo Garcia-Manero, Tapan Kadia, Musa Yilmaz, Gautam Bortakhur, Jan Burger, Steven Kornblau, William Wierda, Courtney DiNardo, Alessandra Ferrajoli, Jovitta Jacob, Rebecca Garris, Susan O'Brien, Elias Jabbour
BACKGROUND: Inotuzumab ozogamicin, an anti-CD22 monoclonal antibody bound to a toxin, calicheamicin, has shown single-agent activity in relapsed or refractory acute lymphoblastic leukaemia. We aimed to assess the activity and safety of inotuzumab ozogamicin in combination with low-intensity chemotherapy in older patients with acute lymphoblastic leukaemia. METHODS: We did a single-arm, phase 2 study at the MD Anderson Cancer Center (Houston, TX, USA). Eligible patients were aged 60 years or older and had newly diagnosed, Philadelphia chromosome-negative, acute lymphoblastic leukaemia, and an Eastern Cooperative Oncology Group performance status of 3 or lower...
February 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29350698/identification-and-management-sinusoidal-obstruction-syndrome-veno-occlusive-disease-eelated-to-hematopoietic-stem-cell-transplantation
#20
Mairéad Ní Chonghaile, Karen Wolownik
BACKGROUND: Sinusoidal obstruction syndrome (SOS), also called hepatic veno-occlusive disease (VOD), is a potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT) that affects about 1 in 7 patients undergoing this procedure. SOS/VOD is caused by the conditioning regimens administered prior to HSCT; in some cases, SOS/VOD results from chemotherapy alone. SOS/VOD usually develops within three weeks following HSCT; however, it can have later onset. 
...
February 1, 2018: Clinical Journal of Oncology Nursing
keyword
keyword
39013
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"